FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

	3	,			

Washington, 5.5. 20040	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287		
	Estimated average burden			

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Biniszkiewicz Detlev</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol iTeos Therapeutics, Inc. [ ITOS ]									k all applic Directo	cable) or	g Pers	son(s) to Iss	vner		
(Last) (First) (Middle) C/O ITEOS THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/17/2021									Officer below)	(give title		Other (s below)	specify	
139 MAIN STREET					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) CAMBRIDGE MA 02142											X	´							
(City)	(S	tate)	(Zip)																
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date, if any (Month/Day/Year)    Execution Date, if any (Month/Day/Year)   Transaction Code (Instr. 8)   Disposed Of (D) (Instr. 3, 6)   Code (Instr. 8)   Code (Ins		Transac Code (I	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)		ed (A) o str. 3, 4	4 and Securitie Benefici		s ally following	Form (D) or	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Pri			ce	Transact (Instr. 3 a	ion(s)			,su. <del>-,</del>							
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security  (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  (Instr. 3)  3. Transaction Date Execution Date, (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)			ate, Tr	ransaction of ode (Instr. Derivative		ve es d ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		5	3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				C	ode \	v	(A)	(D)	Date Exercisabl		expiration Pate	Title	Amou or Numb of Share	ber					
Stock Option (Right to Buy)	\$26.03	06/17/2021			A		16,608		(1)	0	6/17/2031	Common Stock	16,6	808	\$0.00	16,608	3	D	

## **Explanation of Responses:**

1. This stock option shall vest and become exercisable in full upon the earlier to occur of (a) June 17, 2022 or (b) the next annual meeting of the Issuer's stockholders.

## Remarks:

/s/ Michel Detheux, as 06/21/2021 Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).